DEF: Corcept Therapeutics Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals

Corcept Therapeutics will hold its annual stockholder meeting on June 10, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.

Summary

• Corcept Therapeutics Incorporated will hold its Annual Meeting of Stockholders on June 10, 2025, at 7:30 a.m. local time at the company's headquarters in Redwood City, California.
• Stockholders of record as of April 17, 2025, are entitled to vote at the meeting.
• The meeting will address the election of nine directors, ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on the compensation of named executive officers.
• As of the record date, there were 106,044,683 shares of common stock outstanding.
• Directors will be elected by a plurality of the votes cast.
• Adoption of the ratification of the accounting firm and the advisory vote on executive compensation requires the affirmative vote of a majority of the votes cast.
• The proxy statement and accompanying proxy card were first mailed to stockholders on or about April 30, 2025.
• The Board of Directors recommends voting for the election of each director nominee, for the ratification of Ernst & Young LLP, and for the approval of the compensation of named executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The recommendations for voting 'for' the proposals suggest a positive outlook from the board.

Positives

• The Board of Directors is recommending a vote FOR all proposals, indicating confidence in the company's direction and management.
• Stockholders have the opportunity to provide input on key decisions, including the election of directors and executive compensation.

Future Outlook

The document outlines the proposals to be voted on at the 2025 Annual Meeting, setting the stage for the company's governance and operational direction for the coming year.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the key proposals for the upcoming annual meeting, including director elections, auditor ratification, and executive compensation.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key decisions affecting the company's governance and direction.
• The outcome of the votes will influence the composition of the Board of Directors and the company's approach to executive compensation.

Next Steps

• Stockholders should review the proxy statement and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on June 10, 2025.
• The Board will consider the results of the advisory vote on executive compensation when determining future compensation programs.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Directors, Executive Compensation, Ernst & Young, Voting, Corcept Therapeutics